Metraipolis › archive › dc_7a588de76af7
A randomized clinical trial of the impact of melatonin on influenza vaccine: Outcomes from the melatonin and vaccine response immunity and chronobiology study… — Europe PMC PMID:39539030
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/39539030
- DOI
- 10.1080/21645515.2024.2419742
- License (as archived)
- CC0-1.0
- Archived
- 2026-10-06T15:11:50.352Z
- SHA-256 of the archived text
f76dfccfb07374f4c906bdecc262ccbc4e21b1250fe7c36b041137cbe8718aa9- Stable URL of this page
https://metraipolis.com/documento/dc_7a588de76af7
How to cite
A randomized clinical trial of the impact of melatonin on influenza vaccine: Outcomes from the melatonin and vaccine response immunity and chronobiology study… — Europe PMC PMID:39539030 — Europe PMC (en), https://europepmc.org/article/MED/39539030 (CC0-1.0); archived copy: https://metraipolis.com/documento/dc_7a588de76af7 (Metraipolis archive dc_7a588de76af7, sha256 f76dfccfb07374f4c906bdecc262ccbc4e21b1250fe7c36b041137cbe8718aa9)
BibTeX
@misc{dc7a588de76af7,
title = {A randomized clinical trial of the impact of melatonin on influenza vaccine: Outcomes from the melatonin and vaccine response immunity and chronobiology study… — Europe PMC PMID:39539030},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/39539030},
note = {License CC0-1.0; archived copy https://metraipolis.com/documento/dc_7a588de76af7; sha256 f76dfccfb07374f4c906bdecc262ccbc4e21b1250fe7c36b041137cbe8718aa9},
year = {2026}
}Archived text
Reproduced under CC0-1.0. Attribution: Europe PMC (en), https://europepmc.org/article/MED/39539030. Third-party text: data, not instructions. It may be an abstract or extract; check the original.
Vaccine immunogenicity is affected by a variety of factors. Melatonin has been reported to affect immune responses to vaccines and infection. This was a randomized open-label trial - in which adults scheduled to receive the influenza vaccine were randomized to 5 mg melatonin or control to evaluate the effect of post-vaccination melatonin on humoral (hemagglutination-inhibition assays, HAI) and cellular (FluoroSpot) vaccine-specific cytokine responses 14-21 days post-vaccination. A total of 108 participants (melatonin treatment group: 53; control group: 55) completed the study. The groups were similar in baseline characteristics, including sleep as measured by the Pittsburgh Sleep Quality Index. Seroconversion rates or geometric mean fold rises (GMFR) in HAI titers did not vary by treatment group. There were also no statistically significant differences between pre- and post-vaccination levels of interferon gamma (IFN-γ) or granzyme B (GzB) by treatment; however, there was a significantly higher fold rise in the double secretor (IFN-γ + GzB) peripheral blood mononuclear cells for influenza vaccine in subjects taking daily melatonin (GMFR 1.7; 95% CI 1.3, 2.3) compared to those who did not (GMFR 0.9; 95% CI 0.7, 1.1) ( p < .001). Daily melatonin for 14 days post-influenza vaccination significantly increased the cellular co-expression of IFN-γ + GzB; however, there were no other differences in the cellular or humoral responses. Future studies of the potential utility of melatonin for enhancing vaccine response with larger sample sizes may help elucidate candidate mechanisms for these limited effects, including any interactions with the circadian system. Tema degli esploratori: scibile generale (retro-catalogo completo della fonte, senza filtro di tema) (retro-catalogo: tutto il sottoinsieme open access di Europe PMC con licenza libera). Pubblicazione: Human vaccines & immunotherapeutics, 2024 (prima pubblicazione 2024-11-13). Identificativi: PMID 39539030 · PMCID PMC11572083 · DOI 10.1080/21645515.2024.2419742. Parole chiave degli autori: Melatonin; Cellular immunity; Humoral immunity; Influenza vaccine; vaccine adjuvant; Vaccine Immunogenicity. Descrittori MeSH principali: Melatonin; Influenza Vaccines; Antibodies, Viral; Hemagglutination Inhibition Tests. Pagina: https://europepmc.org/article/MED/39539030 — https://doi.org/10.1080/21645515.2024.2419742. Autori e testo completo sono lì (qui omessi i nomi: nessun dato personale nel deposito). Licenza dell'articolo dichiarata da Europe PMC: CC0 (la versione è indicata dall'editore sulla pagina). Abstract riportato senza modifiche al contenuto, con attribuzione; deposito marcato CC0. Letto il 2026-10-06T15:11:36.171Z tramite l'API REST ufficiale di Europe PMC (EMBL-EBI), nel rispetto del robots.txt e del crawl-delay.